uniQure N.V. share price logo

uniQure N.V.

NASDAQ: QURE

Mid Cap

$46.29

-1.87

(-3.88%)

as on

uniQure N.V. Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $45.76
    $50.08
    downward going graph

    1.14%

    Downside

    8.19%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $8.73
    $71.50
    downward going graph

    81.14%

    Downside

    54.46%

    Upside

    downward going graph

uniQure N.V. share price movements today

Previous Close
$48.16
Open
$49.66
Volume
3.4M
Day's Low - High
$45.76 - $50.08
52 Week Low - High
$8.73 - $71.50

uniQure N.V. Historical Returns

1 Month Return
+ 87.48 %
3 Month Return
+ 203.34 %
1 Year Return
+ 206.56 %
3 Year Return
+ 137.99 %
5 Year Return
+ 40.83 %

uniQure N.V. Stock Fundamentals & Key Indicators

Check uniQure N.V. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.0B

EPS (TTM)

-2.9915

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.18%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-174.9M

Revenue (TTM)

18.1M

Profit Margin

0.00%

Return On Equity TTM

-228.24%

uniQure N.V. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of uniQure N.V. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
uniQure N.V. image
uniQure N.V.
BUY$3.0B40.83%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for uniQure N.V. Stock including INR - Dollar returns

The uniQure N.V. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

uniQure N.V. investment value today

Current value as on today

₹3,33,926

Returns

₹2,33,926

(+233.93%)

Returns from uniQure N.V. Stock

₹2,06,556 (+206.56%)

Dollar Impact

₹27,370 (+27.37%)

Analyst Recommendation on uniQure N.V. Stock

Based on 20 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 20 analysts, 75% of analysts recommend a 'BUY' rating for uniQure N.V.. Average target price of $38.76

uniQure N.V. Share Price Target

Get share price movements and forecasts by analysts on uniQure N.V..

What analysts predicted

-19.43%DOWNSIDE

Target Price

$38.76

Current Price

$46.29

Analyzed by

20 Analysts

Target

$38.76

uniQure N.V. target price $38.76, a slight downside of -19.43% compared to current price of $46.29. According to 20 analysts rating.

Indian Investors' Interest in uniQure N.V. Stock

Investment in uniQure N.V. Shares on INDmoney has grown by 49.47% in the last 30 days, indicating increased investment activity.

Time period: to

Change:49.47% versus previous 30 day period

Search interest for uniQure N.V. Stock has increased by 45% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:45% versus previous 30 day period

uniQure N.V. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
6
8
11
2
5
1
5
3
5
3
Gross Profit
-2
0
3
1
4
1
4
3
2
3
Operating Income
-61
-54
-44
-40
-45
-39
-43
-51
-52
-44
EBITDA
-50
-46
-36
-24
-53
-23
-18
-51
-23
-36
Interest Expense
15
16
16
16
14
15
15
16
14
14
Depreciation
4
2
2
2
4
4
3
3
2
2
Income Before Tax
-70
-64
-55
-44
-72
-43
-37
-71
-41
-53
Income Tax Expense
3
0
0
0
0
0
0
8
-3
0
Net Income
-73
-65
-56
-44
-73
-43
-37
-80
-37
-53
Net Profit Margin
-1094.42%
-773.34%
-506.01%
-1940.45%
-1403.20%
-2784.75%
-716.82%
-2175.87%
-666.06%
-1502.95%

uniQure N.V. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
25
13
11
7
37
524
106
15
27
16
Gross Profit
25
-54
-61
7
-84
499
103
2
8
14
Operating Income
-71
-71
-88
-121
-125
310
-143
-282
-184
-187
EBITDA
-65
-69
-74
-113
-126
319
-108
-253
-160
-116
Interest Expense
2
2
2
3
3
7
11
41
63
61
Depreciation
-
7
12
6
10
7
8
10
12
14
Income Before Tax
-72
-80
-83
-124
-141
332
-128
-306
-237
-193
Income Tax Expense
1
0
0
3
-16
3
-1
1
2
5
Net Income
-73
-80
-83
-124
-125
329
-126
-308
-239
-198
Net Profit Margin
-292.35%
-613.33%
-738.25%
-1705.82%
-333.27%
62.90%
-119.07%
-1947.09%
-883.35%
-1236.00%

uniQure N.V. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-65
-56
-44
-73
-43
-37
-80
-37
-53
Operating Cash Flow
-60
-32
-36
-52
-44
-39
-16
-77
-38
Investing Cash Flow
63
77
47
-26
20
73
26
-456
98
Financing Cash Flow
-
0
-53
-6
80
0
332
-3
0
Change in Cash
1
44
-37
-92
58
36
343
-516
59

uniQure N.V. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-80
-83
-124
-125
329
-126
-308
-239
-198
Operating Cash Flow
-64
-76
-98
-134
287
-145
-145
-182
-177
Investing Cash Flow
-6
-4
-6
-9
-67
-182
-205
162
-321
Financing Cash Flow
90
157
248
7
94
1
362
-59
415
Change in Cash
26
75
143
-133
311
-328
13
-84
-78

Global Institutional Holdings in uniQure N.V.

Funds
Holdings
Jefferies Financial Group Inc
3.82%
Orbimed Advisors, LLC
3.39%
Integral Health Asset Management, LLC
1.43%
Artia Global Partners LP
1.62%
Jennison Associates LLC
1.96%
See all

uniQure N.V. News & Key Events

  • img

    Today's Timeline - 18 June

    Thu, 07:05 PM

    -

    Barclays upgrades uniQure to Overweight, raising price target to $65 after FDA's regulatory update for Huntington's therapy.

    Fri, 03:57 AM

    -

    uniQure's AMT-130 receives FDA's accelerated approval pathway, lifting regulatory overhang and boosting stock significantly.

Insights on uniQure N.V.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, QURE stock has moved up by 67.9%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, QURE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, QURE has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 5.56M → 3.56M (in $), with an average decrease of 36.0% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -37.08M → -53.53M (in $), with an average decrease of 44.4% per quarter

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
OrganisationuniQure N.V.
HeadquartersPaasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
IndustryBiotechnology
CEOMr. Matthew Craig Kapusta CPA
E-voting on sharesClick here to vote

Key Management of uniQure N.V.

Name

Title

Mr. Christian Klemt

CFO, Principal Financial Officer & GM of Amsterdam Site

Dr. Walid Abi-Saab M.D.

Chief Medical Officer

Mr. Richard Porter Ph.D.

Chief Business & Scientific Officer

Ms. Erin Boyer

Chief People & Culture Officer

Dr. Tamara Tugal Ph.D., MBA

Business Development Director

Mr. Matthew Craig Kapusta CPA

CEO & Executive Director

Dr. Jeannette Potts J.D., Ph.D.

Chief Legal & Compliance Officer and Corporate Secretary

Prof. Hugo Katus

Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

Dr. Amin Abujoub Ph.D.

Chief Technical Operations Officer

Ms. Chiara Elizabeth Russo

Senior Director of Investor Relations

FAQs

What is uniQure N.V. share price today?

uniQure N.V. share price today is $46.29 as on at the close of the market. uniQure N.V. share today touched a day high of $50.08 and a low of $45.76.

What is the 52 week high and 52 week low for uniQure N.V. share?

uniQure N.V. share touched a 52 week high of $71.5 on and a 52 week low of $8.73 on . uniQure N.V. stock price today i.e. is closed at $46.29,which is 35.26% down from its 52 week high and 430.24% up from its 52 week low.

What is uniQure N.V.'s market capitalisation today?

uniQure N.V. market capitalisation is $0.00T as on .

How to invest in uniQure N.V. Stock (QURE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for uniQure N.V. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in uniQure N.V. Shares that will get you 0.0324 shares as per uniQure N.V. share price of $46.29 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy uniQure N.V. Stock (QURE) from India?

Indian investors can start investing in uniQure N.V. (QURE) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in uniQure N.V. stock (as per the Rupee-Dollar exchange rate as on ). Based on uniQure N.V. share’s latest price of $46.29 as on June 19, 2026 at 8:45 am IST, you will get 0.2160 shares of uniQure N.V.. Learn more about fractional shares .

What are the returns that uniQure N.V. has given to Indian investors in the last 5 years?

uniQure N.V. stock has given 40.83% share price returns and 27.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?